PDCD1 and melanoma: The Food and Drug Administration (FDA) has approved numerous monoclonal antibodies (mAbs) against PD-1 and PD-L1 (nivolumab, pembrolizumab, atezolizumab, and durvalumab) for the treatment of various cancers, including melanoma and NSCLC (30–32).